Cann Group chairman Julian Chick has acquired 250,000 shares in the business, with new chief executive Jenni Pilcher and fellow board member Robert Barnes also investing, as the company looks for a period of stability after a tough resumption of trading.

Cann Group chairman Julian Chick

Chick has invested $10,000, valuing his shares at $0.04c, with Barnes investing the same amount for 200,000 shares, valuing his stocks at $0.05c per share.

Neither have previously held shares in the business.

Pilcher, meanwhile, has acquired 205,500 shares for $9,952, taking her total to 330,500.

Shares in the company fell sharply last week after Cann Group resumed trading after an enforced three-month suspension.

It is currently trading at $0.048c, valuing the company at $21m.

AusCann

Brett Mitchell has resigned as a non-executive board member of AusCann, with Piers Lewis named as his replacement.

Mitchell, the former chairman of MGC Pharmaceuticals, now Argent Biopharma, has been on the board since June 2023.

Lewis has 25 years’ experience in corporate advisory roles and is currently chairman of ASX-listed mining company Aurumin and a non-executive director at OD6 Metals and copper company Noronex.

AusCann last month announced a deal to merge with WA-based ECC Pharma with the combined group planning to list on the ASX.

Emyria

The co-founder of sleep disorder clinic Sleep Studies Australia – now called Western Australia Sleep – has been appointed by Emyria to the newly-created role of general manager of clinical operations.

Simon Kemp helped build the sleep clinic into a national network, generating annual revenues of $3.5m.

Meanwhile, Emyria has announced the resignation of chief financial officer Joseph Ohayon.

Avecho

Avecho Biotechnology has received A$1.07 million from the government’s research and development tax incentive scheme.

The funds will be used to support the company’s on-going schedule 3 clinical trial for insomnia and to advance its commercialisation strategy.

Steve has reported for a number of consumer and B2B titles over a journalism career spanning more than three decades. He is a regulator contributor to health journal, The Medical Republic, writing on...

Leave a comment